Qiagen N.V.
Health
Performance
3.9
Risk
Sell
Buy
Curious about the Scores? Learn more.

Qiagen N.V. stock rating and score history

All changes in ratings, performance and outlook tracked over time.

03.02.2026
Fragile setup. Still failing to meet the key marks today.
21.01.2026
Slight bounce. Could be noise – or a comeback brewing.
01.01.2026
Health’s picking up. Numbers look cleaner, cash flow tighter.
28.08.2025
Still low-risk, but small tremors appearing.
QGEN
Qiagen N.V.
50.95
-0.55%
3.9
Sell
Buy
Qiagen N.V.

Qiagen N.V. stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does Qiagen N.V. do? Business model and key facts

Get the full picture of Qiagen N.V.: what it builds, where it operates, and how it makes money.

Qiagen N.V. Profile

Sector: Healthcare

Industry: Medical - Diagnostics & Research

Employees (FY): 5700

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

shop
Company facts
Thierry Bernard
CEO
5700
Employees worldwide
shop
Performance
27.12%
Last 12 months
-9.33%
Last 5 years
shop
Growth
$1,98B
Revenue year
$83,59M
Net income
shop
Valuation
$10,50B
Market Cap
118.59
Price/Earnings Ratio

Stocks related to Qiagen N.V.

Selected based on industry alignment and relative market positioning.

ICLR
ICON Public Limited Company
150.59
+3.58%
7.0
Sell
Buy
ICON Public Limited Company
RVTY
Revvity, Inc.
101.59
+2.08%
5.0
Sell
Buy
Revvity, Inc.
GH
Guardant Health, Inc.
101.85
+3.55%
8.8
Sell
Buy
Guardant Health, Inc.
CRL
Charles River Laboratories International, Inc.
189.21
+3.00%
8.5
Sell
Buy
Charles River Laboratories International, Inc.
RDNT
RadNet, Inc.
69.24
+7.32%
5.9
Sell
Buy
RadNet, Inc.

Qiagen N.V. fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.